Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Tadamitsu Kishimoto, Sujin Kang
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 323-348
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Targeting IL-6 trans-signalling: past, present and future prospects
Stefan Rose‐John, Brendan J. Jenkins, Christoph Garbers, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 10, pp. 666-681
Open Access | Times Cited: 245
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
Mansur Aliyu, Fatema Tuz Zohora, Abubakar Umar Anka, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109130-109130
Open Access | Times Cited: 152
The advent of immune stimulating CAFs in cancer
Maria Tsoumakidou
Nature reviews. Cancer (2023) Vol. 23, Iss. 4, pp. 258-269
Closed Access | Times Cited: 73
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
Vitaly Chasov, Ekaterina Zmievskaya, Irina Ganeeva, et al.
Antibodies (2024) Vol. 13, Iss. 1, pp. 10-10
Open Access | Times Cited: 18
Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs
Akey Krishna Swaroop, Preeya Negi, Ayushi Kar, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 76, pp. 48-76
Closed Access | Times Cited: 15
Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19
Chisa Matsumoto, Shigeru Shibata, Takuya Kishi, et al.
Hypertension Research (2022) Vol. 46, Iss. 3, pp. 601-619
Open Access | Times Cited: 42
A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice
Gang Jin, Yanyan Liu, Lixia Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 6, pp. 1059-1072
Closed Access | Times Cited: 14
The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases
Minjun Wang, Hailing Zhang, Fei Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Structure of the IL-27 quaternary receptor signaling complex
Nathanael A. Caveney, Caleb R. Glassman, Kevin M. Jude, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 29
Anti‐Acidification and Immune Regulation by Nano‐Ceria‐Loaded Mg–Al Layered Double Hydroxide for Rheumatoid Arthritis Therapy
Hao Fu, Yuedong Guo, Wenming Fang, et al.
Advanced Science (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 18
Structural insights into IL-6 signaling inhibition by therapeutic antibodies
Mingxing Wang, Long Chen, Jin He, et al.
Cell Reports (2024) Vol. 43, Iss. 3, pp. 113819-113819
Open Access | Times Cited: 7
Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects
Е. Л. Насонов
Rheumatology Science and Practice (2024) Vol. 62, Iss. 1, pp. 32-54
Open Access | Times Cited: 7
Roles of RNA-binding proteins in immune diseases and cancer
Shigeru Hashimoto, Tadamitsu Kishimoto
Seminars in Cancer Biology (2022) Vol. 86, pp. 310-324
Closed Access | Times Cited: 27
Perspectives of JAK Inhibitors for Large Vessel Vasculitis
Ryu Watanabe, Motomu Hashimoto
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance
Shigeru Hashimoto, Ari Hashimoto, Ryuta Muromoto, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2618-2618
Open Access | Times Cited: 26
Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis
Andrés González García, Julián Fernández-Martín, Á. Robles Marhuenda
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. 1426-1435
Open Access | Times Cited: 24
Exploring the mechanism of Celastrol in the treatment of rheumatoid arthritis based on systems pharmacology and multi-omics
Liuting Zeng, Ganpeng Yu, Kailin Yang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Drugs targeting CMPK2 inhibit pyroptosis to alleviate severe pneumonia caused by multiple respiratory viruses
Zhongxiang Tang, Yu Mao, Pinglang Ruan, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 5
Closed Access | Times Cited: 5
N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment
Zhiyun Duan, Runhan Shi, Bo Gao, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Fluorinated dendrimer-mediated miR-30a delivery regulates the inflammation of macrophages and mitigates the symptoms of rheumatoid arthritis
Jiakai Xing, Jiaxin Jia, Hugang Zhang, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 1143-1159
Closed Access | Times Cited: 5
New bitongling regulates gut microbiota to predict angiogenesis in rheumatoid arthritis via the gut-joint axis: a deep neural network approach
Yin Guan, Xiaoqian Zhao, Yun Lü, et al.
Frontiers in Microbiology (2025) Vol. 16
Open Access
Normal butanol fraction of Polygonum hydropiper L. flavonoids reduces inflammation caused by PCV2 infections in cell and mouse models
Yuheng Wei, Shu‐Mian Zhou, Wen Zhao, et al.
Frontiers in Veterinary Science (2025) Vol. 12
Open Access
Serum biomarkers in rheumatoid arthritis patients and effect of unani herbal formulation Qurs-e-hudar on these biomarkers suggesting the anti-IL-6 effect
Towseef Amin Rafeeqi, Riyaz Ahmed Pandith, Humma Humma, et al.
Journal of Herbal Medicine (2025), pp. 100999-100999
Closed Access
Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
I. Patrikeeva, Yu. A. Lushpaeva, N. V. Knaub, et al.
Modern Rheumatology Journal (2025) Vol. 19, Iss. 1, pp. 57-63
Open Access
Page 1 - Next Page

Scroll to top